FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely, to pharmacology and oncology, and is intended for producing a medicinal product for treating small cell lung cancer. In order to produce a medicinal product for treating small cell lung cancer that has progressed or relapsed after at least 2 previous different courses of systemic chemotherapy, chiauranib represented by a compound by the formula (I) is applied.
EFFECT: production of an effective medicinal product for treating small cell lung cancer that has progressed or relapsed after at least 2 previous different courses of systemic chemotherapy.
3 cl, 2 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER | 2016 |
|
RU2796903C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS | 2019 |
|
RU2783846C1 |
| NAZARTINIB FOR USE IN THE TREATMENT OF CNS METASTASIS | 2019 |
|
RU2795089C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| RET INHIBITOR FOR USE IN THE TREATMENT OF CANCER WITH RET ALTERATION | 2019 |
|
RU2800951C2 |
| METHODS FOR COMBINATION THERAPY OF PROLIFERATIVE DISEASES | 2011 |
|
RU2577278C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| THERAPEUTIC AGENT FOR BILIARY TRACT CANCER TREATMENT | 2016 |
|
RU2728932C2 |
